Advertisement
Advertisement
NVAX
Novavax Inc
9.03
USDSponsored
-0.31
-3.29%
Mar 26, 14:44 UTC -4
Open
NVAX Earnings Reports
Positive Surprise Ratio
NVAX beat 18 of 41 last estimates.
44%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$80.89M
/-$0.24
Implied change from Q4 25 (Revenue/ EPS)
-45.02%
/-318.18%
Implied change from Q1 25 (Revenue/ EPS)
-87.87%
/-108.19%
Novavax Inc earnings per share and revenue
On Jan 12, 2026, NVAX reported earnings of 0.11 USD per share (EPS) for Q4 25, beating the estimate of -0.49 USD, resulting in a 122.15% surprise. Revenue reached 147.14 million, compared to an expected 92.06 million, with a 59.82% difference. The market reacted with a +17.42% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.24 USD, with revenue projected to reach 80.89 million USD, implying an decrease of -318.18% EPS, and decrease of -45.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Novavax Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Novavax Inc reported EPS of $0.11, beating estimates by 122.15%, and revenue of $147.14M, 59.82% above expectations.
How did the market react to Novavax Inc's Q4 2025 earnings?
The stock price moved up 17.42%, changed from $9.53 before the earnings release to $11.19 the day after.
When is Novavax Inc expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Novavax Inc's next earnings report?
Based on 7
analysts, Novavax Inc is expected to report EPS of -$0.24 and revenue of $80.89M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement